Join us Sept. 24 in NYC to connect with execs from Digitas, Claire's, Marriott, Havas and others
Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Should brands swerve, or steer as F1’s U.S. viewership slows?
Formula One is spending to re-engage fans for the seasons’ second half. With viewership figures under question, should brands seeking to share its growth story worry?
Inside the complex anatomy of agency AI bills
From AI subscriptions to metered token usage, agencies are grappling with a more complicated cost structure and who pays.
Perplexity is betting big on creators
AI companies face a tricky sell: to convince creators to advocate for a technology that many fear could threaten livelihoods.